Publication: Assessment of minimal clinically important improvement by using Oral Health Impact Profile-14 in Behcet's disease
| dc.contributor.authors | Hayran, O.; Mumcu, G.; Inanc, N.; Ergun, T.; Direskeneli, H. | |
| dc.date.accessioned | 2022-03-12T17:38:19Z | |
| dc.date.accessioned | 2026-01-11T14:08:20Z | |
| dc.date.available | 2022-03-12T17:38:19Z | |
| dc.date.issued | 2009 | |
| dc.description.abstract | Objectives. The aim of this prospective study, was to detect minimal clinically important improvement (MCII) of oral health impact profile-14 (OHIP-14) for assessing the effect of treatments for oral ulcers in Behcet's disease (BD). Methods. BD patients with active oral ulcers (F/M:36/22) were selected. Baseline and follow-up data were, collected by clinical examinations and questionnaires. Patients rated their global impression of change (PGIC) measured by a transitional question. MCII was defined as the difference in mean change from baseline in OHIP-14 between patients with no response to therapy; and patients with next higher level of response. Results. Approximately one third (29.3%) of the patients expressed an improvement during control examinations. A significant correlation was observed between raw change in OHIP-14 score and change in number of oral ulcers (r=0.69 p=0.017). Inactive patients increased from 44.1% in baseline to 58.8% in follow-up examination. A trend towards decreased number of oral ulcers was observed in follow-up (0.64 +/- 0.93) compared to baseline (1.44 +/- 1.92) in the improved group (p=0.096). According to regression analysis, PGIC was a significant predictor of change in raw OHIP-14 score. The threshold levels generated from the ROC analyses in OHIP-14 score best associated with clinically important improvement were -3.5 points (sensitivity: 80%, specificity: 88.6%) and -38.1% (sensitivity: 86.7%, specificity: 97.1%) respectively. Conclusion. Changes in OHIP-14 scores seem to be a sensitive and valuable tool for the determination of MCII during follow-up of Behcet's disease patients for oral disease assessment. | |
| dc.identifier.doi | doiWOS:000272424000016 | |
| dc.identifier.eissn | 1593-098X | |
| dc.identifier.issn | 0392-856X | |
| dc.identifier.pubmed | 19796539 | |
| dc.identifier.uri | https://hdl.handle.net/11424/229470 | |
| dc.identifier.wos | WOS:000272424000016 | |
| dc.language.iso | eng | |
| dc.publisher | CLINICAL & EXPER RHEUMATOLOGY | |
| dc.relation.ispartof | CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.subject | MCII | |
| dc.subject | OHIP-14 | |
| dc.subject | oral ulcer | |
| dc.subject | improvement | |
| dc.subject | Behcet's disease | |
| dc.subject | QUALITY-OF-LIFE | |
| dc.title | Assessment of minimal clinically important improvement by using Oral Health Impact Profile-14 in Behcet's disease | |
| dc.type | article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | S84 | |
| oaire.citation.issue | 2 | |
| oaire.citation.startPage | S79 | |
| oaire.citation.title | CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | |
| oaire.citation.volume | 27 |
